Jazz Pharmaceuticals Ireland Limited

6 trials 3 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

16 Countries active

21 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 3

Oversight events:

2 temporary halts across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 3 Breast cancer metastatic 2 Invasive breast carcinoma 1 Colorectal cancer 1 HER2 protein overexpression 1 Salivary gland cancer 1 Breast cancer stage III 1 Ovarian cancer 1 Breast cancer stage II 1 Gastric cancer 1 Non-small cell lung cancer 1 Endometrial cancer 1

Top IMPs

ZANIDATAMAB 6 CISPLATIN 1 DURVALUMAB 1 FULVESTRANT 1 GEMCITABINE 1 OXALIPLATIN 1 PALBOCICLIB 1 TISLELIZUMAB 1

All trials

6 total

A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 Phase II 3 countries ZANIDATAMAB
A Phase 2 study of zanidatamab in patients with HER2-expressing tumors Recruiting

2024-516551-41-00 Phase II 1 country ZANIDATAMAB
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Phase III 8 countries ZANIDATAMAB
An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended

2023-508219-21-00 Phase III 10 countries CISPLATIN; DURVALUMAB; GEMCITABINE; ZANIDATAMAB
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended

2023-510319-20-00 Phase III 12 countries OXALIPLATIN; TISLELIZUMAB; ZANIDATAMAB
Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended

2023-508135-30-00 Phase II 1 country FULVESTRANT; PALBOCICLIB; ZANIDATAMAB

Showing 1–6 of 6 trials

← All sponsors A–Z